Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights
Kenan Aloss, Mallory I Frederick, Saima Hassan · 2026
Read Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights by Kenan Aloss, Mallory I Frederick, Saima Hassan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473525.txt.
Description
Aloss, Frederick, and Hassan review giving PARP inhibitors in sequence for breast cancer in twenty twenty-six. PARP inhibitors block a DNA repair enzyme and help a subset of patients. Mixing them with other drugs at the same time showed little extra benefit. Timing the doses one after another may work better.
Sequential schedules can sustain DNA damage while sparing normal cells. They also suppress repair pathways and stir immune responses. Differences in replication stress between tumor and healthy cells lower toxicity. The review weighs laboratory and clinical evidence for this strategy. It covers pairings with chemotherapy, targeted drugs, and immunotherapy. The authors frame sequencing as a practical way to improve outcomes.
Catalog record
| CREATOR | Kenan Aloss, Mallory I Frederick, Saima Hassan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |